EBR Systems, Inc., developer of the world’s only left ventricular endocardial pacing (LVEP) system for heart failure, announces the appointment of Robert C. Canby, MD, as Chief Medical Officer.
Key Highlights
- Robert Canby, MD, appointed Chief Medical Officer is a board-certified cardiac electrophysiologist who brings extensive experience across clinical practice, physician education, cardiovascular research, and medical device innovation.
- Dr. Canby practices at the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas, and serves as President of the Texas Cardiac Arrhythmia Research Foundation.
- He will continue in his clinical role at St. David’s and will be working on EBR’s behalf as his other duties permit.
- This appointment strengthens EBR’s clinical leadership as the Company advances US commercial adoption and continued clinical development of the WiSE® System.
- He succeeds Dr. Spencer Kubo, who has served as EBR’s Chief Medical Officer since 2019.
Dr. Canby is a board-certified cardiac electrophysiologist with extensive experience spanning clinical practice, physician education, cardiovascular research, and medical device innovation.
He currently practices at the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas, and serves as President of the Texas Cardiac Arrhythmia Research Foundation. Dr. Canby will continue in his clinical role at St. David’s and will be working on EBR’s behalf as his other duties permit.
Dr. Canby, EBR Systems’ Chief Medical Officer, said:
“I am excited to take on the role of EBR Systems’ CMO. I have always been interested in the intersection of technology and better clinical outcomes for our patients. I have seen firsthand the benefit that EBR’s technology has brought to my patients, and I hope that in this new role I can help impact even more patients. This particular technology is so important as it provides physicians with an important tool to treat patients that might otherwise not receive optimal therapy.”
As Chief Medical Officer, Dr. Canby will lead EBR’s medical and clinical strategy, including evidence development, physician education and engagement, and collaboration with the Company’s research and development and commercial teams. He will also help ensure that patient needs continue to guide the development and adoption of the WiSE System.
John McCutcheon, EBR Systems’ President & Chief Executive Officer, said:
“Dr. Canby is a highly respected cardiac electrophysiologist and brings an exceptional combination of clinical expertise, medical device experience and a deep understanding of cardiac electrophysiology.
His perspective as a practicing physician will be invaluable as we scale adoption of the WiSE System and continue our clinical development programs.
We welcome Bob to EBR’s leadership team and look forward to his contribution as we expand access to WiSE for patients who are not well served by conventional CRT.”
He succeeds Dr. Spencer Kubo, who has served as EBR’s Chief Medical Officer since 2019 and is now retiring from industry. Dr. Kubo was instrumental in helping to manage the SOLVE-CRT pivotal study for WiSE and in working with the FDA to gain WiSE approval. EBR wishes to express much gratitude to Dr. Kubo for his significant contributions to EBR.
For more information about EBR, please visit https://www.ebrsystemsinc.com/.
About EBR Systems
EBR Systems is a cardiac rhythm management company on a clear mission: to transform the lives of people with heart failure by helping physicians deliver optimal cardiac pacing. The WiSE System—the first FDA approved system for leadless left ventricular endocardial pacing (LVEP) in CRT—combines advanced engineering with peer-reviewed clinical evidence to expand access for patients who previously lacked options and to improve outcomes.
About the WiSE Technology
The WiSE System delivers LV endocardial pacing without a transvenous LV lead using targeted ultrasound. A subcutaneous transmitter and battery detect the RV pacing signal and, within milliseconds, emit ultrasound energy that a rice-sized endocardial electrode converts into an electrical pulse—enabling synchronized biventricular pacing. This LVEP approach is engineered for versatility across patient anatomies and is supported by peer-reviewed outcomes from SOLVE-CRT pivotal trial. WiSE is approved for commercial use in the United States and limited to clinical study use outside of the United States.
Forward-Looking Statements
This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company’s control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.
All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products and achieve broad market adoption including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products; our expectations with respect to our clinical trials, including enrollment in or completion of our clinical trials and our associated regulatory applications and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. These forward-looking statements are based on EBR Systems’ current expectations and inherently involve significant risks and uncertainties. EBR Systems’ actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of certain risks and uncertainties including those risks described in more detail in its most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other documents on file with the SEC from time to time and available on the SEC’s website at www.sec.gov.
Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.
Foreign Ownership Restriction
EBR’s ASX-traded (ASX: EBR) CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR’s CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261020760082/en/
Media gallery
